Clinical trials: Moderate to Severe Dementia
Alzheimer Disease
Impact of Therapeutic Educational Programme on the Alzheimer's Disease Affected Patient's Quality of Life
Therapeutic education expands in Alzheimer's Disease management in France. Several studies revealed a positive impact on caregiver's burden and/or quality of life.
- Trial name
- THERAD (NCT01796314)
- Testing
- Therapeutic Educational Program
- Where
- France
- Volunteers
- 170 people
- Sponsor
- University Hospital, Toulouse
Dementia of the Alzheimer's Type
A Study of the Safety and Efficacy of Memantine in Moderate to Severe Alzheimer's Disease
The objective of this study is to evaluate the safety, tolerability, and efficacy of memantine compared to placebo in outpatients diagnosed with moderate-to-severe dementia of the Alzheimer's type on a concurrent…
- Trial name
- NCT00322153
- Testing
- memantine ER
- Where
- 83 sites in United States, Argentina and 2 more
- Volunteers
- 677 people
- Sponsor
- Forest Laboratories
Healthy Volunteers, Moderate to Severe Alzheimer Patients
A Randomized SAD and MAD Study Evaluating the Safety and Tolerability of RPh201 in Healthy Subjects and in Adults With Alzheimer's Disease
This is a dual-centre, Phase I/IIa study, in healthy subjects and subjects with AD to investigate the safety, tolerability, cognitive, and behavioural effects of RPh201.
- Trial name
- NCT01513967
- Testing
- RPh201, botanical drug product
- Where
- 2 sites in Canada
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Regenera Pharma Ltd
Schizophrenia Agitation, Schizo Affective Disorder
Evaluating Sublingual Dexmedetomidine For Moderate To Severe Agitation In Inpatients With Schizophrenia Or Bipolar Disorder
An open-label, randomized, active control inpatient trial to evaluate the efficacy and tolerability of sublingual dexmedetomidine for the treatment of agitation in inpatients with schizophrenia or bipolar disorder as measured by…
- Conditions
- Schizophrenia Agitation, Schizo Affective Disorder, Bipolar Disorder, Dexmedetomidine
- Trial name
- NCT06093451
- Testing
- Dexmedetomidine, Lorazepam 2 MG/ML
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Temple University
Alzheimer's Disease
An Evaluation of the Safety and Efficacy of Memantine in Agitated Patients With Moderate to Severe Alzheimer's Disease
About 65% of patients with severe Alzheimer's Disease (AD) will have symptoms of agitation. There are drawbacks associated with the currently available therapeutic interventions for agitation associated with Alzheimer's Disease.
- Trial name
- NCT00097916
- Testing
- memantine HCl
- Where
- 9 sites in United States
- Volunteers
- 34 people
- Sponsor
- Forest Laboratories
Alzheimer Disease
A Phase 3 Efficacy Study Of Dimebon In Patients With Moderate To Severe Alzheimer's Disease
No Dimebon clinical data exist yet in patients with disease that has advanced to the moderate-to-severe stage. Therefore, this study evaluates the safety and efficacy of Dimebon in patients with moderate-to-severe AD who are…
- Trial name
- NCT00912288
- Testing
- Dimebon 20 mg po TID
- Where
- 47 sites in United States, Canada and 6 more
- Volunteers
- 86 people
- Sponsor
- Pfizer
Moderate to Severe Alzheimer's Disease
GV1001 Subcutaneous for the Treatment of Moderate to Severe Alzheimer's Disease(AD)
The objective of this study is to evaluate the safety and efficacy of GV1001 administered subcutaneously in patients with moderate to severe Alzheimer's disease (AD).
- Trial name
- NCT05303701
- Testing
- GV1001 1.12mg
- Volunteers
- 750 people
- Sponsor
- Samsung Pharmaceutical Co., Ltd.
Alzheimer's Disease
Comparison of 23 mg Donepezil Sustained Release (SR) to 10 mg Donepezil Immediate Release (IR) in Patients With Moderate to Severe Alzheimer's Disease
The purpose of this study is to compare 23 mg donepezil sustained release (SR) to the currently marketed formulation of 10 mg donepezil immediate release (IR) in patients with moderate to severe Alzheimer's disease.
- Trial name
- NCT00478205
- Testing
- Aricept (donepezil SR 23 mg), Aricept (donepezil IR 10 mg)
- Where
- United States
- Volunteers
- 1,467 people
- Sponsor
- Eisai Inc.
Alzheimer Disease
Satisfaction With Orodispersible vs Conventional Memantine in Moderate to Severe Alzheimer's Disease
The goal of this clinical study is to evaluate satisfaction with the use of orodispersible Memantine (OD) versus conventional Memantine tablets (MTb) using the validate SATMED-Q in patients with moderate to severe Alzheimer's…
- Trial name
- NCT07417670
- Testing
- Memantine, Memantine Oral Tablet
- Where
- 4 sites in Mexico
- Volunteers
- 105 people
- Sponsor
- Carnot Laboratories
Alzheimer's Disease
Safety and Tolerability of Memantine in Moderate to Severe Alzheimer's Disease
The primary objective of the study was to examine the safety and tolerability of memantine in outpatients with moderate to severe Alzheimer's Disease.
- Trial name
- NCT00857233
- Testing
- Memantine
- Where
- 33 sites in Canada
- Volunteers
- 297 people
- Sponsor
- H. Lundbeck A/S
Alzheimer's Disease
A Phase III Multi Regional Clinical Trial (MRCT) of Tricaprilin in Mild to Moderately Severe Probable Alzheimer's Disease With Optional Open Label Extension
This is Phase 3 study, multi-centre, double-blind, placebo controlled, parallel group to evaluate the effects of AC-SD-03 on the efficacy and safety among participants with mild to moderate Alzheimer's Disease.
- Trial name
- NCT04187547
- Testing
- Tricaprilin
- Sponsor
- Cerecin
Alzheimer's Disease
A Study Assessing Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease
This is a randomized double-blind placebo-controlled study comparing different doses of bryostatin for the treatment of moderately severe to severe Alzheimer's disease.
- Trial name
- NCT02431468
- Testing
- Bryostatin 1
- Where
- 29 sites in United States
- Volunteers
- 147 people
- Sponsor
- Neurotrope Bioscience, Inc.
Treatment, Efficacy
Efficacy and Safety of Memantine and Sodium Oligomannate in Patients With Moderate to Severe Alzheimer's Disease
Alzheimer's disease (AD) is the main cause of dementia. At present, AD is incurable. Memantine is recommended for the treatment of moderate and severe AD patients. Sodium oligomannate (GV-971) is a marine-derived oligosaccharide.
- Conditions
- Treatment, Efficacy, Safety, Alzheimer Disease
- Trial name
- NCT05430867
- Testing
- Memantine Oral Tablet, GV-971 capsule
- Volunteers
- 150 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Alzheimer's Disease
Memantine and Antipsychotics Use
To investigate the potential to reduce concomitant antipsychotic medication use in subjects with moderate dementia of Alzheimer's type, treated with memantine.
- Trial name
- MemAP (NCT00649220)
- Testing
- Memantine
- Where
- Germany
- Volunteers
- 19 people
- Sponsor
- Merz Pharmaceuticals GmbH
Moderate Dementia, Severe Dementia
Can Virtual Reality Reduce Depression and Agitation in Older Adults With Moderate to Severe Dementia?
Dementia is a term used to describe a collection of symptoms including memory loss, problems with reasoning and communication, and a reduction in a person's ability to carry out daily activities.
- Trial name
- NCT04347668
- Testing
- Virtual Reality, Usual Care
- Where
- 3 sites in Canada
- Volunteers
- 266 people
- Sponsor
- Western University, Canada
Moderate to Severe Alzheimer's Disease
Donepezil and Memantine in Moderate to Severe Alzheimer's Disease
The trial will examine whether pharmacological treatment with donepezil, memantine or combination of memantine and donepezil is any better than a placebo (dummy) treatment in people with Alzheimer's disease who have reached the…
- Trial name
- DOMINO-AD (NCT00866060)
- Testing
- Memantine, Donepezil
- Where
- United Kingdom
- Volunteers
- 800 people
- Sponsor
- King's College London
Alzheimer Disease
Efficacy and Safety of Curcumin Formulation in Alzheimer's Disease
Curcumin is shown to impact several different pathways of neuroprotection, however clinical trials have not shown positive results, due to the poor bioavailability of curcumin.
- Trial name
- NCT01001637
- Testing
- Curcumin Formulation
- Where
- India
- Volunteers
- 26 people
- Sponsor
- Jaslok Hospital and Research Centre
Dementia
A Study to Compare Genetic Variations of IGF-I and IGF-II
The purpose of this study is to determine if insulin-like growth factors (IGF) play a role in the development of dementia, specifically Alzheimer's disease (AD).
- Trial name
- NCT01329523
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Avera McKennan Hospital & University Health Center
Alzheimer's Disease
Rivastigmine Monotherapy and Combination Therapy With Memantine in Patients With Moderately Severe Alzheimer's Disease Who Failed to Benefit From Previous Cholinesterase Inhibitor Treatment
This is a prospective, multicenter, open-label study. Following screening and baseline assessments, eligible patients will be switched to rivastigmine and will enter the 16 week run-in rivastigmine treatment phase.
- Trial name
- NCT00234637
- Testing
- Rivastigmine, memantine
- Where
- France
- Volunteers
- 204 people
- Sponsor
- Novartis
DEM, Dementia
Advanced Cognitive Stimulation Therapy (ACST)
This study is a feasibility randomised controlled trial (RCT) for an evidence-based intervention for people with moderate to severe dementia.
- Conditions
- DEM, Dementia, Dementia, Vascular, Dementia, Mixed
- Trial name
- NCT04550975
- Testing
- Advanced Cognitive Stimulation Therapy
- Volunteers
- 32 people
- Sponsor
- University College, London